SRPT Sarepta Therapeutics Inc

Price (delayed)

$71.38

Market cap

$5.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.11

Enterprise value

$5.24B

Sector: Healthcare
Industry: Biotechnology

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights

SRPT's gross profit is up by 47% year-on-year and by 9% since the previous quarter
The revenue rose by 42% YoY and by 9% QoQ
Sarepta Therapeutics's quick ratio has increased by 7% YoY but it has decreased by 4.3% from the previous quarter
SRPT's debt is up by 47% year-on-year and by 40% since the previous quarter
The company's equity fell by 15% QoQ and by 7% YoY

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
79.42M
Market cap
$5.67B
Enterprise value
$5.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.39
Price to sales (P/S)
10.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.7
Earnings
Revenue
$540.1M
EBIT
-$553.07M
EBITDA
-$513.33M
Free cash flow
$25.26M
Per share
EPS
-$7.11
Free cash flow per share
$0.32
Book value per share
$9.65
Revenue per share
$6.93
TBVPS
$38.11
Balance sheet
Total assets
$2.98B
Total liabilities
$2.22B
Debt
$1.07B
Equity
$761.76M
Working capital
$2.07B
Liquidity
Debt to equity
1.41
Current ratio
5.97
Quick ratio
4.9
Net debt/EBITDA
0.84
Margins
EBITDA margin
-95%
Gross margin
88.3%
Net margin
-102.6%
Operating margin
-104.5%
Efficiency
Return on assets
-19.1%
Return on equity
-57.7%
Return on invested capital
-31.3%
Return on capital employed
-21.5%
Return on sales
-102.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
0%
1 week
-0.58%
1 month
-9.16%
1 year
-38.1%
YTD
-58.13%
QTD
-4.23%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$540.1M
Gross profit
$476.72M
Operating income
-$564.16M
Net income
-$554.13M
Gross margin
88.3%
Net margin
-102.6%
SRPT's gross profit is up by 47% year-on-year and by 9% since the previous quarter
SRPT's net margin is up by 45% year-on-year and by 15% since the previous quarter
SRPT's operating margin is up by 44% YoY and by 17% from the previous quarter
The revenue rose by 42% YoY and by 9% QoQ

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
7.39
P/S
10.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.7
The EPS has grown by 27% YoY and by 9% from the previous quarter
SRPT's P/B is 39% below its last 4 quarters average of 12.2 and 13% below its 5-year quarterly average of 8.5
The company's equity fell by 15% QoQ and by 7% YoY
The P/S is 95% less than the 5-year quarterly average of 199.2 and 56% less than the last 4 quarters average of 23.3
The revenue rose by 42% YoY and by 9% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROA has soared by 52% YoY and by 17% from the previous quarter
The ROS has grown by 45% YoY and by 15% from the previous quarter
Sarepta Therapeutics's ROIC has increased by 40% YoY and by 17% from the previous quarter
The return on equity is up by 14% year-on-year and by 6% since the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 34% more than the total liabilities
SRPT's total liabilities has soared by 121% YoY and by 18% from the previous quarter
The total assets has soared by 64% YoY and by 7% from the previous quarter
SRPT's debt is 41% greater than its equity
The debt to equity has surged by 64% since the previous quarter and by 58% year-on-year
SRPT's debt is up by 47% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.